Notice of financing round closing total about 300 million yen

  • Notice of financing round closing total about 300 million yen


Notice of financing round closing totaling about 300 million yen

Notice of completion of financing

Overview of Financing

We are proudly announce that we have closed finance round total of about 300 million yen (on July 9th 2021). Investors are venture capitals that our shareholders. The total amount we raised, was approximately 1.05 billion yen, including this round.

Fund on this round will be used mainly for 1) promotion of research and development and expansion of DDS technology (DDS (Drug Delivery System)), and 2) expansion of nanoparticle supplying system. We are eager to carry out joint research and development with pharmaceutical companies, and strengthen our research system so that drugs can be delivered to patients suffering from central nervous system diseases around the world as soon as possible.

Promotion of joint research with drug delivery system platform “Brain Access™”

The technology to break through BBB (Blood-brain Barrier) and deliver drugs to the brain is regarded as important and researched and developed all over the world, and breakthroughs are still waited. Our drug delivery platform “Brain Access™” is a technology that can deliver various drugs to the brain using nanoparticles which can containing drugs and modifying the surface.
Currently, we are promoting this unique platform “Brain Access™”, and are promoting the business through alliances with pharmaceutical companies and in-house drug discovery research using this technology, which will be further accelerated by this capital increase.

Overview of Underwriters

  • UTokyo Innovation Platform Co., Ltd.
    (Head quarters: Hongo, Bunkyo-ku, Tokyo. President and CEO: Katsuhiko Oizumi)
  • Fast Track Initiative, Inc.
    (Headquarters: Hongo, Bunkyo-ku Tokyo. Managing Partner: Hiromichi Kimura)

Contact for inquiries

Person in charge Business Administration and Finance Department
Phone: +81-3-5805-3417

For inquiries by email, please use the inquiry form